Secondary Cytoreduction in @entity902 -Resistant Recurrent XXXX : A Single-Institution Experience.

@entity43 @entity1 @entity5 @entity260 @entity902
BACKGROUND: The purpose of this study was to observe the role of secondary cytoreductive surgery in @entity902 -resistant recurrent @entity43 ( @entity43 ) @entity1 . METHODS: We collected data of @entity1 affected by recurrent @entity43 treated between 1995 and 2013. Inclusion criteria were: invasive epithelial @entity43 histologically documented, cytoreductive surgery and @entity902 -based chemotherapy at first-line treat ment with evidence of complete response to treatment, disease-free interval <6  months, and no concomitant @entity5 . @entity1 considered susceptible of cytoreductive surgery (group A) were compared with a historical series of @entity1 with similar characteristics but not eligible for surgery (group B). RESULTS: Of 122 @entity902 -resistant @entity1 , 18 met the inclusion criteria for the study and were enrolled. They were compared with a historical series of 18 @entity1 not surgically treated with analogous clinical and pathological features. The most frequent sites of relapse included pelvic and aortic lymph nodes (39  %), peritoneum (33  %), bowel (28  %), and pelvis (22  %). A low rate of @entity260 was reported. No deaths were recorded. Overall survival was significantly longer in cytoreductive group when compared with the control group (P  =  0.035). Median overall survival was 44  months. Estimated 5-year overall survival rates were 57 versus 23.5  % for groups A and B, respectively. CONCLUSIONS: Surgery could represent a useful adjunct to chemotherapy in the management of @entity902 -resistant recurrent @entity43 @entity1 , carefully selected, in highly selected centers. Larger prospective trials are needed to further confirm our experience.
